Skip to main content
. Author manuscript; available in PMC: 2015 Aug 20.
Published in final edited form as: Cancer Biol Ther. 2009 Nov 27;8(22):2186–2193. doi: 10.4161/cbt.8.22.10446

Figure 3. DLD1 expression of p53-responsive EGFP reporter in side population (SP) putative cancer stem cells as compared to non-SP cells exposed to the p53 pathway restoring small molecule ellipticine.

Figure 3

Cells were treated with the indicated dose of ellipticine for 16 hr and then Hoechst 33342 dye was added as described in Materials and Methods followed by flow cytometry to analyze EGFP expression in untreated versus ellipticine-treated SP and non-SP DLD1 cells.